Study Description: Combined Suppression Of Cholesterol Bioavailability And Androgen Deprivation Therapy To Treat Castration Resistant Prostate Cancer
Study Design: Single-arm phase II trial
Trial Status: open to recruitment
Chief Investigator: Prof Hing Leung, Beatson West of Scotland Cancer Centre, Glasgow
Sponsor: University of Glasgow/NHS Greater Glasgow & Clyde
Date Opened: 20th December 2016
Planned Closure Date: December 2018
Target Recruitment: 40 patients
Open to New Sites: Not Applicable, single-centre only
Contact Details:
Clinical Trials Unit, Glasgow (CTUG)
Project Manager:
Laura Alexander [email protected]
Tel: 00 44 (0) 141 301 7212
Fax: 00 44 (0) 141 301 7244
Clinical Trial Co-ordinator:
Avril Trevethan [email protected]
Tel: 00 44 (0) 141 301 7467
Fax: 00 44 (0) 141 301 7228
Cancer Research UK Clinical Trials Unit,
Beatson West of Scotland Cancer Centre,
1053 Great Western Road,
Glasgow, G12 0YN
Click here to download the Initiation Slides
Pharmacovigilance Documentation
Clinical Management Reference Documents
These are the current Summary of Product Characteristics (SmPCs) to be referred to for the clinical management of trial patients:
- Atorvastatin SmPC from 14 January 2019
For queries concerning Pharmacovigilance or the documents acting as the Reference Safety Information please contact:
The Pharmacovigilance Team email: [email protected] or
Telephone: 0141 211 0352/0203/3567/3968 or 0141 232 2068
Version of NCI Common Terminology Criteria for Adverse Events (CTCAE) being used for the study (if applicable): 4.03
Click here to download the CTCAE
